Objective: Insulin and insulin-like growth factor-1 (IGF-1) have vasorelaxant effects in vivo, which is dependent on nitric oxide (NO) production. The aim of this study was to investigate the vasorelaxant responses mediated by insulin and/or IGF-1 in aortas of obese Zucker rats. Methods: The thoracic aortas of eight lean and eight obese Zucker rats (6 months old) were isolated for vasorelaxation analysis. Insulin-induced and IGF-1-induced vasorelaxant responses were evaluated by the isometric tension of aortic rings in the organ bathes. The roles of phosphatidylinositol 3-kinase (PI3K) and nitric oxide synthase (NOS) in vasorelaxant responses were examined by treating selective inhibitors, such as wortmannin (an inhibitor of PI3K) and N o -nitro-L-arginine methyl ester (L-NAME, a NOS inhibitor). In addition, the vascular responses to sodium nitroprusside (SNP), a direct vasodilator of vascular smooth muscle, were examined. Results: The insulin-induced vasorelaxation in aortas of obese rats was significantly decreased, whereas the IGF-1-induced vasorelaxation was significantly increased, compared with that in lean rats. After the pre-administration of wortmannin or L-NAME, the altered insulin-induced or IGF-1-induced vasorelaxation was abolished. There was no significant difference in the SNP-induced vasorelaxation between lean and obese rats. Conclusion: Our findings suggested that the decreased insulin-mediated vasorelaxation in obese rats appeared to be counteracted by the increased IGF-1-mediated vasorelaxation. Furthermore, the NO-dependent pathway was involved in the altered vasorelaxant responses. However, the SNP-induced vasorelaxation was not changed in obese rats.
Introduction
The obese Zucker rat, a genetic model of morbid obesity, presents many of the same metabolic and cardiopulmonary deficits as noted in obese humans, including increased risks of type 2 diabetes mellitus, 1 hypertension, 2 respiratory dysfunction, [3] [4] [5] upper airway narrowing 6 and poor exercise capacity. 7, 8 Various factors, such as insulin resistance, nocturnal hypoxia, hypertension and poor exercise capacity, often observed in the obesity, may directly or indirectly contribute to the excessive rates of cardiovascular diseases and vascular dysfunctions. [9] [10] [11] [12] Abnormalities in vascular functions have been described in obese animals and obese humans such as increased risks of atherosclerosis, endothelial abnormalities, altered vascular inflammatory markers, altered vascular contractile properties, and the imbalance of vasodilators and vasoconstrictors. [13] [14] [15] However, the precise mechanisms of vasodilatory functions in the obesity were not totally understood.
Insulin and insulin-like growth factor-1 (IGF-1) have specific and physiological functions in regulating vascular contractilities in experimental animals and humans as well as they have been shown to cause decreases in vascular resistances. 16 In experimental animals, insulin has differential effects in different vascular beds, exerting vasorelaxant effects on the femoral, aortic, coronary and tail vasculature 16, 17 Insulin-like growth factor-1 has effects on the regulation of vascular tone that are similar to those of insulin, with regional differences in vasorelaxant responses. 18 The endothelium-derived relaxing factor, nitric oxide (NO), appears to be an important mediator of insulininduced and IGF-1-induced vascular relaxations. 17, 19, 20 Both insulin and IGF-1 stimulate NO production and diminish in vivo and in vitro vascular contractilities in intact vessels. 17, 19, 20 Using a specific inhibitor of nitric oxide synthase (NOS), N-monomethyl-L-arginine (L-NMMA), the investigators have demonstrated that insulin-mediated and IGF-1-mediated vasorelaxations are highly dependent on vascular NO production. 20, 21 The signaling pathways of NO formation involve tyrosine kinase and phosphatidylinositol 3-kinase (PI3K) activities. 21 Both insulin and IGF-1 mediate vascular relaxations mainly through activating PI3K and NOS to further modulate vascular tones. 16, 22 In previous study, a diminished ability of insulin to attenuate vasocontractile responses was found in obese rats. 23 Disturbances of NO have been reported in both obese animals and humans. 1, 24 Nevertheless, the roles of the PI3K and NOS on insulin-mediated and IGF-1-mediated vascular relaxations in the obesity are still unexplored. Sodium nitroprusside (SNP), a direct vasodilator of vascular smooth muscle, induces endothelium-independent vasodilatory responses. The arteriolar dilation of skeletal muscle in response to SNP was reduced in hypertensive diabetic obese Zucker rats, compared with lean rats. 25 However, SNPmediated vasorelaxation of the descending thoracic aorta was not changed in insulin-resistant obese rats. 26 Until now, the vascular responses to SNP are still controversial in the obese animal models. Therefore, the purpose of this study was to investigate whether the altered insulin-mediated or IGF-1-mediated vasorelaxation occurs in the isolated thoracic aortas of obese Zucker rats. Also, the roles of PI3K and NOS in the NOdependent vasorelaxant pathway were examined. Furthermore, the SNP-induced vasorelaxation in aortic rings of obese rats was observed. We hypothesized that altered insulin-mediated and IGF-1-mediated vasorelaxations occurred in morbidly obese Zucker rats, compared with lean rats. A parallel study design was used, with lean, agematched Zucker rats serving as controls.
Materials and methods

Animals
The studies were performed on eight lean (Fa/Fa or Fa/fa) and eight obese (fa/fa) age-matched 6-month-old male Zucker rats. Animals were born by female (Fa/fa) and male (Fa/fa) breeders purchased from Charles River Laboratory in France. One lean and one obese rat were obtained from the same breeder and were housed per cage. Ambient temperature was maintained at 251C and the animals were kept on an artificial 12-h light-dark cycle. The light period began at 07:00 hours. Rats were provided with standard laboratory chow (Lab Diet 5001; PMI Nutrition International Inc., Brentwood, MO, USA) and water ad libitum. All protocols were approved by the Institutional Animal Care and Use Committee of the National Cheng Kung University, Tainan, Taiwan and the principles of laboratory animal care (NIH publication) were followed.
Evaluation of vasorelaxant responses
All rats were weighed and killed under general anesthesia with ether inhalation. The thoracic aortas were immediately isolated for various experiments described below. The vasorelaxant responses were recorded using the isometric tension of aortic rings, of which complete details had previously been provided. 11, 12 The isolated vessel rings of thoracic aortas (3- 
Israel) to evoke vasorelaxant responses. The vasorelaxant responses (i.e. vasorelaxation), which are defined as reduction in tension of the walls of the blood vessels, were expressed as percentages of the precontractile force.
In some phenylephrine-precontracted vessels, the vasorelaxant responses to 10 À9 mol/l SNP (an NO donor) (Merck, Darmstadt, Germany), a direct vasodilator of vascular smooth muscle, were also examined to observe whether the vascular responses were affected in obese rats.
Examination of phosphatidylinositol 3-kinase and nitric oxide synthase in vasorelaxant responses
The possible roles of PI3K and NOS in the insulin-induced or IGF-1-induced vasorelaxant responses were examined by no inhibitor or pre-administration of either wortmannin (3 Â 10 À7 mol/l; an inhibitor of PI3K) (Sigma Chemical), or
NOS inhibitor) (Sigma Chemical) into the oxygenated organ chambers 15 min before the administration of phenylephrine.
Statistical analysis
All data presented in the figures and texts were means7s.e.m. Sample sizes were indicated by 'n'. Body weights of lean and obese rats were tested by unpaired Student's t-test.
The responses of vasorelaxation were analyzed by the analysis of variance using the general linear model in a one between (lean and obese) and one within (different drugs) design. Differences in the responses of vasorelaxation among 
À7
-10 À5 mol/l) caused a concentration-dependent vasorelaxation ( Figure 1 ). Downward shift of the concentration-response curve for insulin was found in obese Zucker rats ( Figure 1 ). The insulin-induced vasorelaxation was significantly (Po0.05) reduced in thoracic aortas of obese rats compared with that in lean rats.
Insulin-like growth factor-1-induced Vasorelaxation
Similarly, IGF-1 (3 Â 10 À9 -10 À7 mol/l) was added cumulatively when the aortic ring was precontracted with phenylephrine (10 À7 mol/l). The administration of IGF-1 (3 Â 10
À9
-10 À7 mol/l) induced a concentration-dependent vasorelaxation in lean and obese Zucker rats (Figure 2 ). Upward shift of the concentration-response curve for IGF-1 was found in obese Zucker rats (Figure 2 ). In contrast with the insulininduced vasorelaxation, the IGF-1-induced vasorelaxation was significantly (Po0.05) elevated in thoracic aortas of obese Zucker rats compared with that in lean rats.
Roles of phosphatidylinositol 3-kinase and nitric oxide synthase in insulin-induced vasorelaxation The insulin-induced vasorelaxation in lean and obese Zucker rats was greatly diminished by the preincubation with wortmannin (3 Â 10 À7 mol/l; an inhibitor of PI3K) or L-NAME (3 Â 10 À7 mol/l; a NOS inhibitor). Before the administration of wortmannin or L-NAME, the vascular response to 3 Â 10 À6 mol/l of insulin in the obese rats was significantly lower than that in the lean rats (Po0.05; Figure 3 ). When wortmannin was added, insulin-evoked vasorelaxation was significantly reduced in either lean or obese groups, and the group difference between lean and obese rats disappeared. Similar results were observed when the vessels were pretreated with L-NAME ( Figure 3 ). The pretreatment of L-NAME also inhibited insulin-evoked vasorelaxation in either lean or obese groups and attenuated the group difference between lean and obese rats.
Roles of phosphatidylinositol 3-kinase and nitric oxide synthase in insulin-like growth factor-1-induced vasorelaxation The IGF-1-induced vasorelaxation in lean and obese Zucker rats was also greatly diminished by the preincubation with wortmannin (3 Â 10 À7 mol/l) or L-NAME (3 Â 10 À7 mol/l). In contrast with insulin-induced vasorelaxation, the vascular Vasorelaxation in obesity A-L Yang et al response to 10 À8 mol/l of IGF-1 in the obese rats was significantly higher than that in the lean rats before the administration of wortmannin or L-NAME (Po0.05; Figure 4) . Moreover, the pretreatment of wortmannin or L-NAME significantly inhibited IGF-1-evoked vasorelaxation and attenuated the group difference between lean and obese rats ( Figure 4 ).
Relaxation responses to sodium nitroprusside
The relaxation responses to SNP (10 À9 mol/l), a direct vasodilator of vascular smooth muscle, were the same between lean and obese Zucker rats ( Figure 5 ). It indicated that obesity did not affect the downstream signaling pathways of NO in rat smooth muscle.
Disscussion
Our results clearly demonstrated that: (1) in comparison with age-matched lean rats, the insulin-induced vasorelaxation was significantly decreased in thoracic aortas of obese Zucker rats, whereas the IGF-1-induced vasorelaxation was significantly increased; (2) after the administration of wortmannin or L-NAME, the altered insulin-induced or IGF-1-induced vasorelaxation was abolished; (3) the SNPinduced vasorelaxation was not affected in obese Zucker rats compared with lean rats. The isolated thoracic aortas measured by the isometric tension of aortic rings precontracted with phenylephrine in the organ baths were used in the present study. All vasorelaxant responses were presented in percentage of the precontractile force of phenylephrine. Phenylephrine, a synthetic sympathomimetic agent, is an alpha-adrenergic agonist vasoconstrictor and is a well-developed agonist for pre-contracting vascular rings. The insulin and IGF-1 concentrations used in this study were modified according to the previous study. 27 Consistently, lower sensitivity of insulin-induced vasorelaxation and higher sensitivity of IGF-1-induced vasorelaxation were found in both lean and obese rats. Many reports have indicated that the fasting level of insulin was significantly increased in obese Zucker rats, compared with lean rats. Otherwise, the circulating IGF-1 level was similar between lean and obese rats. .05 and ## Po0.01, with the inhibitor (wortmannin or L-NAME) vs without the inhibitor. The group difference between lean and obese rats was disappeared after the pretreatment of wortmannin or L-NAME (n ¼ 6). 
À7 mol/l). *Po0.05, obese vs lean; # Po0.05 and ## Po0.01, with the inhibitor (wortmannin or L-NAME) vs without the inhibitor. The group difference between lean and obese rats was disappeared after the pretreatment of wortmannin or L-NAME (n ¼ 6). Vasorelaxation in obesity A-L Yang et al to stimulate NO production from endothelial and smooth muscle cells. 16 As the vessel ring contains both endothelium and smooth muscle, any effect of the insulin-mediated or IGF-1-mediated vasorelaxation in the current study cannot be clarified whether this response exists in endothelial, smooth muscle cells or both. Further studies are required to look into specific mechanisms of vasorelaxant responses mediated by insulin and IGF in endothelium or smooth muscle of obese rats. Besides, our data obtained from obese rats in 6 months of age may only represent the altered vasorelaxant mechanism in mature obesity, which may not be suitable for younger obesity or ageing obesity. The vascular function may be potentially interacted with various factors, often seen in the obesity, such as hypertension, volume overload, hypoxia, other hormonal disorders, oxidative stress and physical inactivity. 9-15 Therefore, we have to add a note of caution that any effect on vascular changes in the obesity noted in the present investigation cannot be isolated to any specific interacting factors, such as hypertension, volume overload, nocturnal hypoxemia, oxidative stress or other unclear factors. The present study indicated that, compared with lean rats, the insulin-induced vasorelaxation in thoracic aortas of obese Zucker rats was significantly decreased, whereas the IGF-1-induced vasorelaxation was significantly increased. In consistent with previous study, a diminished ability of insulin to attenuate vasocontractile responses was reported in obese rats. 23 Besides, IGF-1 has been demonstrated to function as a vasodilator that is similar to those of insulin. 18 Therefore, the increased IGF-1-induced aortic vasorelaxation in obese Zucker rats might imply that the impaired insulinmediated vasorelaxation appear to be counteracted with the upregulated IGF-I-mediated vasorelaxation in obese rats. We speculate that our findings in obese Zucker rats could be useful models for investigating similar vascular pathophysiologic conditions occurred in obese animals or obese human. Insulin and IGF-1 mediate vascular relaxation mainly through the NO-dependent pathway involving the PI3K and NOS activities. 16, 22 In our study, after the administration of wortmannin (an inhibitor of PI3K) or L-NAME (a NOS inhibitor), no significant difference of the insulin-induced or IGF-1-induced vasorelaxation was found between lean and obese groups. These findings suggested that the decreased insulin-mediated vasorelaxation in obese Zucker rats was mainly due to the reduced release of PI3K and NOS in the NO-dependent vasorelaxant pathway. On the contrary, the increased IGF-1-mediated vasorelaxation in the obesity was due to the elevated level of PI3K and NOS. Similar results in human leg vessels were found in the previous study. In 20 lean and 20 obese human subjects, intra-arterial infusions of L-NMMA (an inhibitor of NOS) alone produced an approximately 40% increase in the leg vascular resistance, which was not statistically different between two groups. 14 In another study, it has been reported that the IGF-1-induced vasorelaxation was greater, the IGF-1 receptor was elevated and the endothelial NOS expression was also increased in thoracic aortas of streptozotocin (STZ)-induced diabetic rats. 27 It indicated that this change of vasorelaxant response was associated with the alteration of IGF-1 receptor level in diabetic rats. In addition, insulin treatment could further increase the aortic IGF-1 receptors in STZ-induced diabetic rats. 27 However, whether hyperinsulinemia or other biochemical factors contribute to the upregulation of vascular IGF receptors in diabetic rats or diabetic obese rats remain unknown. Further studies should be conducted to explore, in the obesity, whether the levels of insulin or IGF-1 receptors and their underlying mechanisms may contribute to the change of the insulin-induced or IGF-1-induced vasorelaxation.
The SNP-induced relaxation in the thoracic aortas of obese Zucker rats was not altered in our study. It indicated that the endothelium-independent NO pathway in vascular smooth muscle was not affected in the obesity. Vasorelaxation in response to SNP in different obese animal models appeared to be still controversial. In insulin-resistant obese rats, the SNP-induced vasorelaxation of the descending thoracic aorta was not changed. 26 In addition, no significant difference was observed in vascular response to SNP in adiponectin-knockout obese mice compared with wild-type mice. 30 However, the arteriolar dilation of skeletal muscle in response to SNP was reduced in hypertensive diabetic obese Zucker rats compared with lean rats. 25 We speculated that different findings of the vascular responses to SNP may be due to different pathophysiologic conditions (e.g. hypertensive or diabetic), different age or different vascular beds. Obesity has recently been recognized as a major modifiable risk factor for cardiovascular disease, second only to cigarette smoking. 31 Excess weight and obesity markedly increase the risk for hypertension, diabetes, coronary artery disease, congestive heart failure and abnormalities in the vascular function in both men and women. [13] [14] [15] 31 Our current findings indicating 'the decreased insulin-mediated vasorelaxation in obese rats appear to be counteracted with the increased IGF-1-mediated vasorelaxation' might provide one of the possible mechanisms to explain the development and compensation of vascular dysfunction in the obesity. Also, we found that the effects of obesity on vasorelaxant responses mediated by insulin or IGF-1 were mainly due to the altered release of PI3K and NOS. Clinically, when considering possible therapeutic agents to control or prevent the development of vascular dysfunction in the obesity, it should be paid attention on actions of insulin and IGF-1 on the vasorelaxant responses.
